Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Percheron Therapeutics ( (AU:PER) ) has shared an update.
Percheron Therapeutics has applied to the Australian Securities Exchange for quotation of 172,031,809 new ordinary fully paid shares, marking a significant addition to its listed capital base. The issuance, lodged as a new announcement under Appendix 2A, formalizes the move to have these securities traded on the ASX, potentially enhancing liquidity for existing shareholders and expanding the company’s access to public market funding.
The new share quotation follows transactions previously flagged to the market, indicating the company is progressing its capital-raising or restructuring plans. By advancing this substantial block of securities to quotation, Percheron Therapeutics signals an active approach to capital management, which may influence its financial flexibility and visibility among investors in the Australian life sciences sector.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an Australian-listed company in the therapeutics sector, trading on the ASX under the code PER. The company issues ordinary fully paid shares and operates under the Australian corporate and securities regulatory framework, reflecting its focus on capital market financing to support its activities in biotechnology or pharmaceutical development.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.61M
Learn more about PER stock on TipRanks’ Stock Analysis page.